Natco Pharma Ltd Share Price Today - Natco Pharma Ltd Stock Price Live NSE/BSE

Natco Pharma Ltd

NSE: NATCOPHARM BSE: 524816

₹1095.75

(0.20%)

Thu, 07 May 2026, 11:45 am

MTF 5xInvest in Natco Pharma Ltd with 5x Leverage Buy with MTF

Market Cap195.89B

PE Ratio12.60

Dividend0.46

Health Technology

Pharmaceuticals: Major

24.5K

Natco Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
20600.32
Net Profit
1883.40
P/B
1.88
Sector P/E
33.75
P/E
7.57
EV/EBITDA
4.85
Debt/Equity (Industry)
0.24
Interest Cover (Industry)
9.69
ROCE (Industry)
13.46
RONW (Industry)
12.65
ROE
27.98
ROCE
32.48
Debt/Equity
0.05
EPS (TTM)
86.94
Dividend Yield
0.52
Book Value
482.93
Interest Cover
96.87

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.8x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (9.2x coverage).
NATCO Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
Cash flow for NATCO Pharma is expected to increase by more than 50% in 2 years time.

Cons

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
NATCO Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
NATCO Pharma's net income is expected to increase but not above the 50% threshold in 2 years time.
NATCO Pharma's revenue is expected to increase but not above the 50% threshold in 2 years time.
NATCO Pharma's revenue is expected to grow by 15.7% yearly, however this is not considered high growth (20% yearly).

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	49.42	49.48	49.48	49.56	49.56
FII	17.37	15.16	14.09	15.51	17.49
DII	5.46	5.39	5.87	5.82	5.65
Public	27.75	29.96	30.56	29.11	27.29
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

69.82

MACD

32.77

50 DMA

1024.61

200 DMA

911.65

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1382.48	1226.08	1160.92	1069.68	1004.52	913.28	756.88
Fibonacci	1226.08	1166.34	1129.43	1069.68	1009.94	973.03	913.28
Camarilla	1138.76	1124.42	1110.09	1069.68	1081.41	1067.08	1052.74

Pivots Level: Classic

+312.80

1382.48

+156.40

1226.08

+91.23

1160.92

1069.68

Pivot Point

LTP: 1155.20

-65.17

1004.52

-156.40

913.28

-312.80

756.88

Moving Average

SMAEMA

Period

Value

10-EMA
1116.13
20-EMA
1091.89
30-EMA
1069.47
50-EMA
1032.23
100-EMA
978.36
200-EMA
952.78

Announcement Date	Purpose	Action	Ex Date
12 Feb 2026	dividend	₹1.50 Dividend /Share	18 Feb 2026
12 Feb 2026	board-meetings	Quarterly Results, Interim Dividend
18 Jan 2026	dividend	Interim Dividend - Rs 1.50 Per Share	18 Feb 2026
14 Nov 2025	board-meetings	Quarterly Results, Interim Dividend
14 Nov 2025	dividend	₹1.50 Dividend /Share	20 Nov 2025
20 Oct 2025	dividend	Interim Dividend - Rs. - 1.5	20 Nov 2025
28 Aug 2025	agm
12 Aug 2025	dividend	₹2.00 Dividend /Share	19 Aug 2025
19 Jul 2025	dividend	Interim Dividend - Rs. - 2	19 Aug 2025
12 Feb 2025	dividend	₹1.50 Dividend /Share	18 Feb 2025

Natco Pharma Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Cipla Ltd

Lupin Ltd

Natco Pharma Ltd About

Natco Pharma is engaged in the business of pharmaceuticals and agricultural chemicals which comprises research and development, manufacturing and selling of bulk drugs, finished dosage formulations.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1981

Headquarters

CEO

V C Nannapaneni

Employees

Contact

Website

http://www.natcopharma.co.in

investors@natcopharma.co.in

Phone

91-040-23547532

Location

Natco House, Road No 2 Banjara Hills, Hyderabad, Telangana, 500033

Year	History
2020	Announced launch of Lapatinib Tablets for breast cancer in US. Supported Columbia University's clinical trial of chloroquine phosphate for Covid-19. Received establishment inspection report (EIR) for Kothur formulation facility. Vizag formulation facility received USFDA approval.
2021	Launched Tipanat tablets in India for advanced colorectal and gastric cancer. Announced launch of 10mg strength Everolimus Tablets (generic for Afinitor) in US market. Natco Pharma (Canada) Inc. launched PrNAT-LENALIDOMIDE Capsules, first generic alternative to Revlimid. Received approval for Carfilzomib Vials ANDA (generic for KYPROLIS) in US market. Signed Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India. Received final approval for Everolimus tablets (generic for Afinitor) for US market.
2022	Launched Chlorantraniliprole (CTPR) product NATGEN. Signed license agreement with Medicines Patent Pool, Switzerland. Awarded Corporate Governance Award. Completed acquisition of Dash Pharmaceuticals LLC.
2023	Launched generic Pomalidomide Capsules in Canada. Received final approval for Tipiracil Hydrochloride and Trifluridine (generic for Lonsurf) for the US market.
2024	Partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Buy	1199044	904.19	26 Nov 2025
GRAVITON RESEARCH CAPITAL LLP	Sell	1199411	904.93	26 Nov 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	1784917	929.71	24 Apr 2025
GRAVITON RESEARCH CAPITAL LLP	Sell	1784917	930.19	24 Apr 2025
GRAVITON RESEARCH CAPITAL LLP	Sell	971727	891.03	14 Feb 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	971727	890.86	14 Feb 2025
EAST BRIDGE CAPITAL MASTER FUND I LTD	Buy	1577761	528	05 Jul 2019
CX SECURITIES LIMITED	Sell	1198400	930.03	28 Jun 2017
MV SCIF MAURITIUS	Buy	174903	1149.56	20 Jun 2014
MERRILL LYNCH CAPITAL MARKET ESPANA SA SV	Sell	199668	589.55	29 Jul 2013

Natco Pharma Ltd News

NATCO Pharma Files SEBI Disclosure for FY26

NATCO Pharma Limited submitted substantial acquisition/disposal disclosures under SEBI regulations for FY26, confirming no encumbrance of promoter shares during the financial year ended March 31, 2026.

30 Apr 2026

companies

Natco Pharma Files Q4FY26 SEBI Compliance Certificate

Natco Pharma Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4FY26, confirming proper dematerialization processes and compliance with depository regulations through March 31, 2026.

08 Apr 2026

companies

Natco Pharma completes postal ballot for director reappointments

Natco Pharma successfully reappointed four key directors through postal ballot voting conducted in March 2026, with all resolutions receiving overwhelming shareholder approval above 98%.

25 Mar 2026

companies

Natco Pharma Board Approves Demerger & Subsidiary Plans

Natco Pharma board approves agrochemicals demerger scheme with 1:1 share ratio, Nigeria subsidiary incorporation with USD 100,000 investment, and Australia subsidiary liquidation.

24 Mar 2026

companies

Natco Pharma Board Approves Demerger & Subsidiary Plans

Natco Pharma board approves agrochemicals demerger scheme with 1:1 share ratio, Nigeria subsidiary incorporation with USD 100,000 investment, and Australia subsidiary liquidation.

24 Mar 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800

Natco Pharma Ltd

Natco Pharma Share Price Live Chart

Summary

Analysis

Financials

Ratios

Shareholding

Technical Analysis

Corporate Actions

Peer Comparison

Natco Pharma Ltd About

Contact

Natco Pharma Ltd Company History

Deals

Natco Pharma Ltd News